Bevacizumab (Avastin ○ R) Bevacizumab (Avastin ○ R, rhuMAb-VEGF, Genetech Inc.) Receptor humanized antibody against vascular endothelial growth

factor (VEGF), is currently the treatment of colorectal cancer and breast cancer stage Ⅲclinical studies. VEGF regulate angiogenesis, regulation of vascular

permeability and function of anti-apoptotic effects on endothelial cells of neovascularization. Bevacizum ˉ ab monotherapy tumor has made a significant

therapeutic effect, can also enhance anti-tumor efficacy of chemotherapy. In the treatment of metastatic renal cell carcinoma, phase II clinical study in

advance to achieve the expected efficacy endpoint, achieved good efficacy of combination therapy with Xeloda metastatic breast cancer, has entered the

FDA's expedited procedures.


Related Articles: TNF-alpha